All Oncology News

December 6, 2020 — TTI-622, an investigational CD47 inhibitor, showed preliminary signs of clinical activity with a manageable safety profile among patients with relapsed/refractory lymphoma.

December 6, 2020 — The investigational TKI asciminib was found to be a safe and effective treatment for patients with chronic myeloid leukemia without any alternatives in clinical practice, particularly those with prior TKI intolerance and those who achieved prior complete cytogenetic response.

December 6, 2020 — The antibody-drug conjugate belantamab mafodotin continued to showcase efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma, inducing durable responses even in those who had previously received 7 or more lines of therapy.

December 6, 2020 — The BCMA and CD3 bispecific T-cell redirecting antibody TNB-383B elicited significant responses when administered at a higher dose level and was well tolerated at all doses examined in heavily pretreated patients with relapsed/refractory multiple myeloma.

December 6, 2020 — Patients with hematologic malignancies are at increased risk for significant morbidity and mortality from coronavirus disease 2019, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment

December 6, 2020 - UCART22, an allogeneic off-the-shelf CD22-directed T-cell product, showed no unexpected toxicities at 2 dose levels and had early signs of activity in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

December 6, 2020 - Having a human leukocyte antigen–matching donor for allogeneic hematopoietic stem cell transplant has proven to lead to improved outcomes for patients who are between 50 and 75 years of age and have higher-risk myelodysplastic syndrome.

December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

December 5, 2020 - The addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.

The anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.

December 5, 2020 - Axicabtagene ciloleucel demonstrated high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

December 5, 2020 - Patients with previously untreated chronic lymphocytic leukemia /small lymphocytic lymphoma who received a placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease.

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

December 5, 2020 - The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.

December 5, 2020 - Momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.

December 5, 2020 - Patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors saw better overall survival, spleen response, and symptom response with higher doses of the telomerase inhibitor imetelstat.

December 5, 2020 - Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.

December 5, 2020 - Selinexor demonstrated a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma, regardless of age.

December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

December 5, 2020 - KO-539, an oral, selective menin-inhibitor, demonstrated activity in patients with relapsed/refractory acute myeloid leukemia in preliminary findings from the ongoing first-in-human KOMET-001 trial.

December 5, 2020 - Ruxolitinib was found to elicit a significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement versus best available therapy in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.

December 4, 2020 - The completion of the biologics license application for balstilimab in the treatment of patients with recurrent or metastatic cervical cancer has been delayed to the first half of 2021.

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

With the shift away from chemoimmunotherapy, and the adoption of novel combinations, as well as cellular therapy, the MCL treatment landscape has entered a new era. Looking forward, minimal residual disease is bound to play a critical role in terms of guiding treatment selection.

Nigerian patients with prostate cancer are noted as having higher levels of total plasma peroxide, malondialdehyde, and nitric oxide, as well as lower levels of total antioxidant capacity, even while undergoing androgen-deprivation therapy compared with Nigerian men who don't have prostate cancer.